%0 Journal Article
%T Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics.
%A Kohlmann W
%A Nix DA
%A Pauley K
%A Greenberg S
%A Atkinson A
%A Boucher KM
%A Kolesar J
%A Singer EA
%A Edge SB
%A Churchman ML
%A Graham L
%A Salhia B
%A Sanchez A
%A Zakharia Y
%A Nepple KG
%A Schneider BP
%A Byrne L
%A Jain RK
%A Chahoud J
%A Feng BJ
%A Gupta S
%J JCO Precis Oncol
%V 8
%N 0
%D 2024 Jun
%M 38976819
%F 5.479
%R 10.1200/PO.23.00697
%X <B>OBJECTIVE: </B>This study investigates a real-world multicenter cohort of patients with urinary tract cancer (UTC), with primary disease sites including the bladder, urethra, and upper tract, who enrolled for research molecular testing of their germline and tumor. The purpose of this study was to evaluate factors that could affect the likelihood of identifying a clinically actionable germline pathogenic variant (PV).<BR><B>METHODS: </B>Patients with UTC were identified from 10 cancer institutes of the Oncology Research Information Exchange Network consortium. The data set comprised abstracted clinical data with germline and tumor genomic data, and comparative analyses were conducted.<BR><B>RESULTS: </B>Clinically actionable germline PVs in cancer predisposition genes were identified in 16 (4.5%) of 354 patients. A higher proportion of patients with the urethra and the upper tract as the primary sites of disease had PVs with a prevalence of 11% (5/45), compared with only 3.6% (11/308) in those with the bladder as the primary site of disease (P = .04). There were no significant differences in markers of genomic instability (such as tumor mutational burden, microsatellite instability [MSI], and loss of heterozygosity, copy number, and chromosomal instability) between those with PVs and those without (P > .05). Of the PVs identified, 10 (62%) were in homologous recombination repair (HRR) genes, three (19%) in mismatch repair (MMR) genes, and three (19%) in genes associated with other pathways.<BR><B>CONCLUSIONS: </B>Tissue-based assessment of genomic instability, such as MSI, does not reliably indicate germline PV. A comprehensive clinical germline testing approach that includes HRR genes in addition to MMR genes is likely to yield PVs in approximately one of 10 patients with nonbladder primary disease sites such as the upper tract and the urethra.